)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Allakos
Allakos (ALLK) investor relations material
Allakos has been delisted
Allakos Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary7 May, 2025
Executive summary
Entered into a Merger Agreement with Concentra Biosciences for a $0.33/share cash tender offer, expected to close in May 2025 if conditions are met.
Discontinued development of lead candidate AK006 after negative Phase 1 results; initiated a 75% workforce reduction and strategic alternatives review.
Net loss for Q1 2025 was $26.2 million, a significant improvement from $71.1 million in Q1 2024, primarily due to lower R&D costs and absence of impairment charges.
Cash, cash equivalents, and investments totaled $55.2 million as of March 31, 2025, expected to fund operations for at least 12 months.
Financial highlights
Q1 2025 net loss: $26.2 million vs. $71.1 million in Q1 2024; basic and diluted net loss per share: $0.29 vs. $0.81.
Research and development expenses decreased to $13.5 million from $34.8 million year-over-year, reflecting lower clinical and manufacturing costs.
General and administrative expenses increased to $13.2 million from $10.9 million, mainly due to costs associated with facility exit.
No impairment charges in Q1 2025; Q1 2024 included a $27.3 million impairment of long-lived assets.
Interest income declined to $0.7 million from $2.0 million due to lower investment balances.
Outlook and guidance
Cash and investments expected to fund operations for at least the next 12 months.
If the merger is not completed, the board may pursue dissolution and liquidation.
No new research or clinical programs initiated; focus remains on strategic alternatives.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Allakos
- Q2 net loss narrowed to $26.7M; $123.1M cash funds operations into mid-2026 as AK006 advances.ALLK
Q2 2024 - Q3 net loss narrowed, cash runway extended to mid-2026, and AK006 trials progress.ALLKQ3 2024
- AK006 was safe but ineffective in CSU, prompting discontinuation and major restructuring.ALLKStudy Result
- Q4 2024 net income driven by lease gain; AK006 discontinued and major restructuring underway.ALLKQ4 2024
Allakos
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Allakos Inc. is a biopharmaceutical company focused on the development of antibody-based therapies for the treatment of allergic, inflammatory, and proliferative diseases. The company's primary approach involves targeting specific immune cells and inflammatory pathways that contribute to diseases such as eosinophilic gastritis and other related gastrointestinal and inflammatory conditions. Allakos leverages proprietary antibody technologies to create potential therapeutic options aimed at improving outcomes for patients with limited treatment choices. The company is headquartered in San Carlos, California, and its shares are listed on the NASDAQ.